XFLH Capital targeted in reverse merger with Renogen Biolab

Renogen Biolab Inc. signed a letter of intent on September 22, 2026, to acquire XFLH Capital Corporation (NYSE: XFLH) through a reverse merger. In this structure, a private company — here, Renogen Biolab — absorbs a publicly listed shell to gain a stock-market listing without a traditional IPO. The letter of intent is a preliminary agreement only; no completed transaction has been announced.

For holders, the deal signals a potential change of business entirely, as the surviving entity would effectively be Renogen Biolab operating under the listed vehicle. Short interest is minimal at roughly 0.04% of the free float, with only around 4,000 shares shorted, so the short side is not a material factor here. Cost to borrow sits at around 22%, though the negligible short position means that figure has little practical significance at current levels.